Eli Lilly under pressure as Alzheimer's application delayed

The treatment has hit a stumbling block related to Medicare coverage.

Photo: Mike Blake/REUTERS / X00030

Shares in Eli Lilly dropped by 1.7 percent in value on Thursday, after the leadership team at the US-based pharmaceutical company revealed that their plans to apply for marketing authorization for its Alzheimer’s treatment have been delayed.

According to Bloomberg News, this is because Biogen is struggling to get Medicare coverage for its Alzheimer’s drug, Aduhelm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs